If you have been reading about LC-MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-19. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
The end goal of wound care is to re-establish the integrity of the skin, a structure which serves as a barrier to the external environment. The preferred method of closure is to reattach/reapproximate the wound edges together, a process known as primary closure/healing by primary intention. Wounds that have not been closed within several hours of the initial injury or wounds that are concerning for infection will often be left open and treated with dressings for several days before being closed 3–5 days later, a process known as delayed primary closure. The exact duration of time from initial injury in which delayed primary closure is preferred over primary closure is not clearly defined. Wounds that cannot be closed primarily due to substantial tissue loss can be healed by secondary intention, a process in which the wound is allowed to fill-in over time through natural physiologic processes. When healing by secondary intention, granulation tissue grows in from the wound edges slowly over time to restore integrity of the skin. Healing by secondary intention can take up to months, requires daily wound care, and leaves an unfavorable scar, thus primary closure is always preferred when possible. As an alternative, wounds that cannot be closed primarily can be addressed with skin grafting or flap reconstruction, typically done by a plastic surgeon. There are several methods that can be implemented to achieve primary closure of a wound, including suture, staples, skin adhesive, and surgical strips. Suture is the most frequently used for closure.
He then encounters Eddie at a computer in the company boardroom, who demands his release for making the reactor work. Paul agrees but Lyman refuses, so Eddie sets the reactor to explode while sending proof of his innocence to the FBI and blueprints of the reactor to "hopefully a couple thousand" international scientists. Lyman responds by shooting Chen dead, then locking in Eddie and Lily to die in the explosion as he, Paul, and their staff flee the site. Lyman is given a falsified copy of the fusion data before Paul kills him for overstepping the bounds of the program, leaving his body in an elevator. During his own escape, he deactivates the containment system, allowing Eddie and Lily to escape. They are attacked by Reed and Butler over an ascending construction lift but escape by climbing aboard it moments before a blast wave sweeps through the complex, incinerating the corpses of Reed, Butler, and Lyman. Having survived the shockwave, Eddie and Lily are met by FBI agents Ford and Doyle, now convinced of their innocence, who take them to safety. Paul is shown dictating a memo to Anita in a chauffeured limo, informing the Director of the CIA that "...C-System [is] no longer a viable entity." In a post-credits scene, the C-Systems facility is seen imploding into the landscape.
A writer for Business Insider called it one of the best performances of DiCaprio's career, and Ian Sandwell of Digital Spy particularly liked the duo's chemistry, believing their scenes together to be some of the film's strongest parts. DiCaprio received nominations for an Oscar, a Golden Globe, a BAFTA Award and a Screen Actors Guild Award for Best Actor. The film earned $374 million against a budget of $90 million. In 2020, DiCaprio served as an executive producer for The Right Stuff, a television series adaption of the 1973 namesake book. After being in development at National Geographic, it was released on Disney+. That May, DiCaprio briefly featured in the finale of the miniseries The Last Dance. In 2021, DiCaprio appeared in Adam McKay's satirical comedy Don't Look Up. He spent five months changing the film's script with McKay before agreeing to the part. Starring alongside Jennifer Lawrence as two astronomers attempting to warn humanity about an extinction-level comet, DiCaprio saw this film as an analogy of the world's indifference to the climate crisis. As a frequent supporter of environmentalism, DiCaprio said he has often looked to star in and make films tackling issues related to it, something he found hard due to people's inability to listen. He praised McKay for envisioning a project on how humans would react to a serious issue from a political, social and scientific standpoint. While reviews for the film were mixed, most critics praised DiCaprio's and Lawrence's performances; journalists from Digital Spy and NDTV lauded their pairing.
=== Insomnia === In all of the reported cases, the need for sleep was severely reduced and in some cases not necessary. The duration of sleep in one case decreased to about 2–4 hours per 24-hour period. Clinical features pertaining to insomnia include daytime drowsiness associated with a loss of ability to sleep, intermingled with confusional oneiric status, and the emergence of atypical REM sleep from wakefulness. The polysomnogram (PSG) picture of this disease is characterized by an inability to generate physiological sleep (key features are the suppression of the hallmarks of stage 2 non-REM sleep: spindles and K complexes) and by the emergence of REM sleep without atonia. The involvement of the thalamus and connected limbic structures in the pathology indicate the prominent role that the limbic thalamus plays in the pathophysiology of sleep. In a case documented in 1974, PSG findings documented the sustained absence of all sleep rhythms for up to a period of 4 months. Electroencephalography (EEG) in one case was dominated by "wakefulness" and “subwakefulness” states alternating or intermingled with short (< 1 min) atypical REM sleep phases, characterized by a loss of muscle atonia. The “subwakefulness” state was characterized by 4–6 Hz theta activity intermingled with fast activity and desynchronized lower voltage theta activity, behaviourally associated with sleep-like somatic and autonomic behavior.
Sources: en.wikipedia.org
SR-17018 was subsequently assessed in rhesus monkeys and produced analgesic effects in this species that could be reversed by the MOR antagonist naltrexone, whereas respiratory depression could not be assessed due to solubility limitations. While conventional opioids like morphine produced robust itch-scratching behaviors, SR-17018 and buprenorphine only caused mild such effects, suggesting low-efficacy MOR activation. Although SR-17018 was reported to produce very little respiratory depression in mice, a subsequent study using oral administration instead of intraperitoneal administration, with the former having greater bioavailability, unexpectedly found significant respiratory depression with the drug. SR-17018 produced less analgesic tolerance than other MOR agonists in mice. Whereas morphine and oxycodone produced robust tolerance in the hot plate test with chronic administration, SR-17018 produced no or only slight tolerance in this assay depending on the dosage. In addition, whereas morphine caused MOR desensitization in the periaqueductal gray (PAG), a key brain area implicated in the analgesic effects of MOR agonists, SR-17018 produced no desensitization. Similarly, unlike morphine, SR-17018 did not cause upregulation of forskolin-stimulated cAMP accumulation in striatal membranes. Despite the preceding findings however, discontinuation of both morphine and SR-17018 caused withdrawal symptoms in mice, though withdrawal symptoms were lower with SR-17018 compared to morphine.
Azacitidine, sold under the brand name Vidaza among others, is a medication used for the treatment of myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia. It is a chemical analog of cytidine, a nucleoside in DNA and RNA. Azacitidine and its deoxy derivative, decitabine (also known as 5-aza-2′-deoxycytidine) were first synthesized in Czechoslovakia as potential chemotherapeutic agents for cancer. The most common adverse reactions in children with juvenile myelomonocytic leukemia include pyrexia, rash, upper respiratory tract infection, and anemia.
This reaction is part of biochemical pathway called the hydantoinase process which converts 5-substituted hydantoins into optically pure D- or L-amino acids. This enzyme is a hydrolase which act on carbon-nitrogen bonds other than peptide bonds, specifically in linear amides. The systematic name of this enzyme class is N-carbamoyl-L-amino acid amidohydrolase.
== See also == All pages with titles beginning with Thin All pages with titles containing Thin Body shape Emaciation Underweight Paper Thin (disambiguation) Thin capitalisation Thin client, a computer in a client-server architecture network. Thin film, a material layer of about 1 μm thickness. Thin-layer chromatography (TLC), a chromatography technique used in chemistry to separate chemical compounds Thin layers (oceanography), congregations of phytoplankton and zooplankton in the water column Thin lens, lens with a thickness that is negligible compared to the focal length of the lens in optics Thin Lizzy, Irish rock band formed in Dublin in 1969 Thin Man (disambiguation) The Thin Blue Line (disambiguation)
==== Early career (1999–2004) ==== After having a slow start with a season high of 15 Disposals and 4 Marks, in his second season he suffered an injury and missed most of Essendons games. In McVeigh's third season however, it was clear that the game had grown on him as he stood up as an up-and-coming youngster. After playing 23 games in his third year of playing including the Grand Final against the Brisbane Lions in which Essendon lost, McVeigh had some promising stats with a consistent 11 – 18 in over half of every game he played. McVeigh also went on to play the next 3 seasons in stellar form with Essendon who reached 3 consecutive semi-finals in which McVeigh played in all.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.